Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.

Matilde Bjørn ØrumFrederikke F RönsholtMajbritt JeppesenElisabeth BendstrupTerese L KatzensteinPeter OttMichael PerchTacjana PresslerTavs QvistSøren Jensen-Fangel

Published in: Pediatric pulmonology (2022)

We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.

Keyphrases

end stage renal disease
cystic fibrosis
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
mesenchymal stem cells
deep learning
data analysis